New hope for Tough-to-Treat lung cancer: experimental drug trial
NCT ID NCT05117242
Summary
This study is testing an experimental drug called acasunlimab (GEN1046) for people with advanced non-small cell lung cancer that has returned or stopped responding to standard immunotherapy. Researchers want to see if the drug works better when given alone or combined with another cancer drug (pembrolizumab). About 125 participants will be randomly assigned to receive one of the treatment combinations to compare safety and effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliera Universitaria Policlinico G Rodolico San Marco
Catania, Italy
-
Cancer & Hematology Centers of Western Michigan CHCWM P.C.
Grand Rapids, Michigan, 49503, United States
-
Centro Clinico Champalimaud
Lisbon, Portugal
-
Centro Hospitalar Universitário do Porto - Hospital de Santo Antonio
Porto, Portugal
-
Cheltenham General Hospital
Cheltenham, United Kingdom
-
Clinica Universidad de Navarra
Pamplona, Spain
-
Clinica Universidad de Navarra CUN
Madrid, Spain
-
Department of Internal Medicine II
Regensburg, Germany
-
Erasmus MC
Rotterdam, Netherlands
-
Florida Cancer Center
St. Petersburg, Florida, 33705, United States
-
Florida Cancer Specialists - FCS South
Fort Myers, Florida, 33901, United States
-
Fundacion Instituto Valenciano de Oncologia
Valencia, Spain
-
Gustave Roussy
Villejuif, France
-
Henry Ford Cancer Institute
Detroit, Michigan, 48202, United States
-
Hopital Charles Nicolle Chu Rouen
Rouen, France
-
Hopital Morvan CHU de Brest
Brest, France
-
Hopital dInstruction Des Armees Begin
Saint-Mandé, France
-
Hospital Universitari Vall dHebron
Barcelona, Spain
-
Hospital Universitario 12 de Octubre
Madrid, Spain
-
Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain
-
Hospital Universitario Virgen de la Victoria
Málaga, Spain
-
Hôpital Foch
Suresnes, France
-
IFO Regina Elena
Roma, Italy
-
IRCCS Istituto Europeo di Oncologia
Milan, Italy
-
Institut Bergonie
Bordeaux, France
-
Institut de Cancerologie Strasbourg Europe (ICANS)
Strasbourg, France
-
LKI Lungenfachklinik Immenhausen
Immenhausen, Germany
-
La Maddalena SPA
Palermo, Italy
-
Leids Universitair Medisch Centrum
Leiden, Netherlands
-
MD Anderson Cancer Center
Madrid, Spain
-
Maria Sklodowska-Curie National Research Institute of Oncology
Warsaw, Poland
-
Med.Hochschule Hannover Klinik für Pneumologie
Hanover, Germany
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Netherlands Cancer Institute
Amsterdam, Netherlands
-
Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc
Olsztyn, Poland
-
St. Joseph Heritage Healthcare
Santa Rosa, California, 95403, United States
-
The Christie Hospital
Manchester, United Kingdom
-
UOC Oncoematologia AOU L.Vanvitelli
Naples, Italy
-
Universitatsklinik Giessen und Marburg Standort Giessen
Hessen, Germany
-
VU University Medical Center
Amsterdam, Netherlands
Conditions
Explore the condition pages connected to this study.